APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Somatostatin Analogues (LA SSAs)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long-acting Somatostatin Analogues (LA SSAs) Industry Growth and Trends Forecast to 2032

28 December 202599 pages

Choose your research edition.

Industry ResearchLong-acting Somatostatin Analogues (LA SSAs) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Somatostatin Analogues (LA SSAs) Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Long-acting Somatostatin Analogues (LA SSAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting Somatostatin Analogues (LA SSAs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting Somatostatin Analogues (LA SSAs) include Chiesi Farmaceutici S.p.A, Ipsen, Recordati Rare Diseases, Novartis and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long-acting Somatostatin Analogues (LA SSAs) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long-acting Somatostatin Analogues (LA SSAs) market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long-acting Somatostatin Analogues (LA SSAs) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long-acting Somatostatin Analogues (LA SSAs).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Long-acting Somatostatin Analogues (LA SSAs) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long-acting Somatostatin Analogues (LA SSAs) Market by Company

Chiesi Farmaceutici S.p.A

Ipsen

Recordati Rare Diseases

Novartis

Teva

Long-acting Somatostatin Analogues (LA SSAs) Segment by Type

Injections

Oral Capsules

Long-acting Somatostatin Analogues (LA SSAs) Segment by Application

Neuroendocrine Tumors

Acromegaly

Other

Long-acting Somatostatin Analogues (LA SSAs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Somatostatin Analogues (LA SSAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Somatostatin Analogues (LA SSAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Somatostatin Analogues (LA SSAs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting Somatostatin Analogues (LA SSAs) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Long-acting Somatostatin Analogues (LA SSAs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injections Table 2. Major Company of Oral Capsules Table 3. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 5. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Type (2021-2026) Table 6. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (US$ Million) Table 7. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Type (2021-2026) Table 8. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2026) & (US$/Unit) Table 9. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 10. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Type (2027-2032) Table 11. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (US$ Million) Table 12. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Type (2027-2032) Table 13. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2027-2032) & (US$/Unit) Table 14. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 15. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 17. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 21. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (US$ Million) Table 24. Long-acting Somatostatin Analogues (LA SSAs) Industry Trends Table 25. Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers Table 26. Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges Table 27. Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints Table 28. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Company (2021-2026) Table 30. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Company (2021-2026) & (K Units) Table 31. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Company (2021-2026) Table 32. Global Long-acting Somatostatin Analogues (LA SSAs) Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Long-acting Somatostatin Analogues (LA SSAs) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Long-acting Somatostatin Analogues (LA SSAs) Major Company Production Sites and Headquarters Table 35. Global Long-acting Somatostatin Analogues (LA SSAs) Company, Product Type & Application Table 36. Global Long-acting Somatostatin Analogues (LA SSAs) Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Long-acting Somatostatin Analogues (LA SSAs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026) & (K Units) Table 41. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Region (2021-2026) Table 42. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026) & (US$ Million) Table 43. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Region (2021-2026) Table 44. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2027-2032) & (K Units) Table 46. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Region (2027-2032) Table 47. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2027-2032) & (US$ Million) Table 48. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Region (2027-2032) Table 49. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 52. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Application (2021-2026) Table 53. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (US$ Million) Table 54. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Application (2021-2026) Table 55. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 57. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Application (2027-2032) Table 58. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (US$ Million) Table 59. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Application (2027-2032) Table 60. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2027-2032) & (US$/Unit) Table 61. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 62. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 64. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 68. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (US$ Million) Table 71. Chiesi Farmaceutici S.p.A Company Information Table 72. Chiesi Farmaceutici S.p.A Business Overview Table 73. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 75. Chiesi Farmaceutici S.p.A Recent Development Table 76. Ipsen Company Information Table 77. Ipsen Business Overview Table 78. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 80. Ipsen Recent Development Table 81. Recordati Rare Diseases Company Information Table 82. Recordati Rare Diseases Business Overview Table 83. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 85. Recordati Rare Diseases Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 90. Novartis Recent Development Table 91. Teva Company Information Table 92. Teva Business Overview Table 93. Teva Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 95. Teva Recent Development Table 96. North America Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 97. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 98. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2026) Table 99. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032) & (K Units) Table 100. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share Forecast by Country (2027-2032) Table 101. North America Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026) & (US$ Million) Table 103. North America Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country (2021-2026) Table 104. North America Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. North America Long-acting Somatostatin Analogues (LA SSAs) Market Share Forecast by Country (2027-2032) Table 106. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 107. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 108. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2026) Table 109. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032) & (K Units) Table 110. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share Forecast by Country (2027-2032) Table 111. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026) & (US$ Million) Table 113. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country (2021-2026) Table 114. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Share Forecast by Country (2027-2032) Table 116. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 118. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2026) Table 119. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032) & (K Units) Table 120. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026) & (US$ Million) Table 123. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country (2021-2026) Table 124. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Share Forecast by Country (2027-2032) Table 126. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 128. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2026) Table 129. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032) & (K Units) Table 130. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share Forecast by Country (2027-2032) Table 131. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026) & (US$ Million) Table 133. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country (2021-2026) Table 134. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Share Forecast by Country (2027-2032) Table 136. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 138. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2026) Table 139. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032) & (K Units) Table 140. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026) & (US$ Million) Table 143. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country (2021-2026) Table 144. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Share Forecast by Country (2027-2032) Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Long-acting Somatostatin Analogues (LA SSAs) Distributors List Table 149. Long-acting Somatostatin Analogues (LA SSAs) Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Long-acting Somatostatin Analogues (LA SSAs) Image Figure 2. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (2021-2032) & (K Units) Figure 5. Injections Image Figure 6. Global Injections Sales YoY Growth (2021-2032) & (K Units) Figure 7. Oral Capsules Image Figure 8. Global Oral Capsules Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Long-acting Somatostatin Analogues (LA SSAs) Market Share by Type 2025 VS 2032 Figure 11. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Type in 2025 Figure 12. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Type in 2025 Figure 13. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Type in 2025 Figure 14. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Type in 2025 Figure 17. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Long-acting Somatostatin Analogues (LA SSAs) Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Neuroendocrine Tumors Image Figure 24. Global Neuroendocrine Tumors Sales YoY Growth (2021-2032) & (K Units) Figure 25. Acromegaly Image Figure 26. Global Acromegaly Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Long-acting Somatostatin Analogues (LA SSAs) Market Share by Application 2025 VS 2032 Figure 31. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Application in 2025 Figure 32. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Application in 2025 Figure 33. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Application in 2025 Figure 34. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Application in 2025 Figure 37. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share in Value by Application in 2025 Figure 41. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Long-acting Somatostatin Analogues (LA SSAs) Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Injections
  • Oral Capsules
Applications
  • Neuroendocrine Tumors
  • Acromegaly
  • Other
Companies covered
  • Chiesi Farmaceutici S.p.A
  • Ipsen
  • Recordati Rare Diseases
  • Novartis
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Long-acting Somatostatin Analogues (LA SSAs) Market by Type
  6. 1.3.1 Injections
  7. 1.3.2 Oral Capsules
  8. 1.4 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Type
  9. 1.4.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Long-acting Somatostatin Analogues (LA SSAs) Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Long-acting Somatostatin Analogues (LA SSAs) Industry Trends
  2. 2.2 Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers
  3. 2.3 Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges
  4. 2.4 Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2026)
  2. 3.2 Global Top Players by Long-acting Somatostatin Analogues (LA SSAs) Sales (2021-2026)
  3. 3.3 Global Top Players by Long-acting Somatostatin Analogues (LA SSAs) Price (2021-2026)
  4. 3.4 Global Long-acting Somatostatin Analogues (LA SSAs) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting Somatostatin Analogues (LA SSAs) Major Company Production Sites & Headquarters
  6. 3.6 Global Long-acting Somatostatin Analogues (LA SSAs) Company, Product Type & Application
  7. 3.7 Global Long-acting Somatostatin Analogues (LA SSAs) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting Somatostatin Analogues (LA SSAs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting Somatostatin Analogues (LA SSAs) Tier 1, Tier 2, and Tier 3
4 Long-acting Somatostatin Analogues (LA SSAs) Regional Status and Outlook
  1. 4.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Historic Market Size by Region
  3. 4.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Long-acting Somatostatin Analogues (LA SSAs) Forecasted Market Size by Region
  7. 4.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Long-acting Somatostatin Analogues (LA SSAs) by Application
  1. 5.1 Long-acting Somatostatin Analogues (LA SSAs) Market by Application
  2. 5.1.1 Neuroendocrine Tumors
  3. 5.1.2 Acromegaly
  4. 5.1.3 Other
  5. 5.2 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Application
  6. 5.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chiesi Farmaceutici S.p.A
  2. 6.1.1 Chiesi Farmaceutici S.p.A Company Information
  3. 6.1.2 Chiesi Farmaceutici S.p.A Business Overview
  4. 6.1.3 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  6. 6.1.5 Chiesi Farmaceutici S.p.A Recent Developments
  7. 6.2 Ipsen
  8. 6.2.1 Ipsen Company Information
  9. 6.2.2 Ipsen Business Overview
  10. 6.2.3 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  12. 6.2.5 Ipsen Recent Developments
  13. 6.3 Recordati Rare Diseases
  14. 6.3.1 Recordati Rare Diseases Company Information
  15. 6.3.2 Recordati Rare Diseases Business Overview
  16. 6.3.3 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  18. 6.3.5 Recordati Rare Diseases Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Teva
  26. 6.5.1 Teva Company Information
  27. 6.5.2 Teva Business Overview
  28. 6.5.3 Teva Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  30. 6.5.5 Teva Recent Developments
7 North America by Country
  1. 7.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country
  2. 7.1.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026)
  4. 7.1.3 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  6. 7.2.1 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026)
  8. 7.2.3 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country
  2. 8.1.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026)
  4. 8.1.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  6. 8.2.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country
  2. 9.1.1 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  6. 9.2.1 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country
  2. 10.1.1 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026)
  4. 10.1.3 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  6. 10.2.1 South America Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026)
  8. 10.2.3 South America Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country
  2. 11.1.1 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  6. 11.2.1 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Long-acting Somatostatin Analogues (LA SSAs) Value Chain Analysis
  2. 12.1.1 Long-acting Somatostatin Analogues (LA SSAs) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process
  7. 12.2 Long-acting Somatostatin Analogues (LA SSAs) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Long-acting Somatostatin Analogues (LA SSAs) Distributors
  10. 12.2.3 Long-acting Somatostatin Analogues (LA SSAs) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst